Vapotherm invented HFNC and now sells an advanced form of HFNC that provides high flow at a high velocity, rapidly flushing the dead space in the limited time between breaths when respiratory rates ...

Respiratory care specialist Vapotherm raised $56 million in an initial public offering of 4 million shares, priced at the low end of the range at $14. The Exeter, New Hampshire-based company plans to ...

Vapotherm to Expand Production Capacity in Advance of Potential Increase in Demand for High-Flow Nasal Cannula Systems for Treating COVID-19 Respiratory Distress Increased capacity anticipated to ...

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced it has received 510(k) clearance from the US Food and Drug Administration for HVT 2.0. This next generation system is ...

Increased capacity anticipated to scale capital production by up to 20X above pre-COVID-19 pandemic levels At maximum capacity, increased production could create up to 350 manufacturing jobs in New ...

Infinium Medical, through its Infinium Veterinary division will be exclusively distributing Vapotherm VET 2.0 high-velocity respiratory therapy systems. This partnership allows us to provide ...